Data from a recent trial of EVO301, a long-acting injectable interleukin-18 binding protein, show that the anti-IL-18 protein was effective for the treatment of moderate-to-severe atopic dermatitis (AD) in adults.
The popularity of GLP1 medications in the United States has increased significantly, driven by their effectiveness in weight management and diabetes treatment. The market potential for these drugs is substantial,
The regenerative movement is gaining momentum, harnessing the body’s natural healing processes to repair or replace damaged skin tissue, and dermatology professionals are embracing exciting new therapies and procedures. Guided
Off-label use — prescribing a medication for an indication, patient population, dose, or route not specifically approved by regulatory agencies — is a legal and widely accepted practice in dermatology
The U.S. Food and Drug Administration (FDA) has accepted the resubmission of a Biologics License Application (BLA) for relabotulinumtoxinA (Relfydess), a next-generation neuromodulator under review for the temporary improvement of
Originally developed for the treatment of type 2 diabetes, GLP-1 receptor agonists (GLP-1 RAs) have more recently been used in obesity management and metabolic disease. Emerging research now suggests that
The FDA’s recent report evaluating the use of perfluoroalkyl and polyfluoroalkyl substances (PFAS) in cosmetic products revealed significant uncertainty due to gaps in existing data on PFAS exposure through cosmetics.
As consumers continue to lean into self-care and wellness trends, the nail care industry is expanding, with a 2024 global market value of $8.8 billion that is forecasted to keep
The official launch of Le-Vel’s exosome-based skin system, XERA, on Dec. 16 marks what the company describes as a new era in skin repair, restoration, and renewal. “XERA represents a
Conexeu Sciences Inc. has reported a milestone in regenerative medicine with the creation of the first 3D-printed tissue structures from its patented functional extracellular matrix (ECM). While the company is
A new study led by Northwestern Medicine and the University of California, San Francisco offers compelling evidence that tanning beds mutate skin cells far beyond the effects of ordinary sunlight
The U.S. Food and Drug Administration (FDA) has proposed adding bemotrizinol to its list of permitted active ingredients for use in sunscreens — marking the agency’s first potential addition of
The future of Artificial Intelligence (AI) in dermatology is being explored with a mixture of confidence and caution. AI shows promise for improving patient-clinician interactions and supporting personalized care in
A significant breakthrough in understanding the causes of hypersensitivity in sensitive skin was presented at the 50th Convention of the Japanese Cosmetic Science Society. Researchers from the Kao Company highlighted
The recent passage of the SAFE Sunscreen Standards Act (H.R. 3686/S. 2491), which modernizes how the U.S. Food and Drug Administration (FDA) reviews and approves sunscreen ingredients, marks an important advancement
Chronic spontaneous urticaria impacts roughly 1.7 million people in the United States, underscoring the need for improved therapies. Data presented at the American College of Allergy, Asthma & Immunology Annual
The U.S. Food and Drug Administration (FDA) recently approved Restylane Lyft with Lidocaine for augmentation of the chin region to improve the chin profile in patients aged 21 and older
In a recent safety communication, the U.S. Food and Drug Administration (FDA) issued a warning to consumers, patients, and health care providers about serious complications reported in connection with certain
As dermatology continues to embrace diversity and inclusivity, increasing attention is being paid to the unique needs of patients with skin of color. A recent reanalysis of a study in
The FDA has approved adalimumab-aaty (YUFLYMA; Celltrion, Inc.) for the treatment of adolescent hidradenitis suppurativa (HS) and pediatric uveitis (UV) in the U.S. This approval, which covers both YUFLYMA and
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
